Journal article icon

Journal article

IGF-1 regulates cancer cell immune evasion in prostate cancer

Abstract:
Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in other models. We investigated IGF-1’s tumor-intrinsic immune effects in PCa to understand mechanisms underlying its poor immunotherapy response. Transcriptional profiling of human (DU145, 22Rv1) and murine (Myc-CaP) PCa cells revealed that IGF-1 suppresses cytokine signalling, antigen processing and presentation, and additional immune regulatory pathways. We further examined the expression of components involved in cancer cell recognition and immune evasion: the antigen processing machinery and PD-L1 checkpoint. IGF-1 downregulated key elements such as transporters associated with antigen processing (TAPs), endoplasmic reticulum aminopeptidase-1 (ERAP-1), and Class I β2-microglobulin, without significantly altering Class I allele expression. These changes were associated with reduced surface presentation of Class I complexes on Myc-CaP cells, suggesting disrupted peptide transport, processing, and/or presentation. In contrast, IGF-1 upregulated the immune checkpoint CD274 (PD-L1) via IGF receptor/AKT/ERK-dependent signalling. Analysis of TCGA Firehose Legacy PCa data showed higher CD274 expression in tumors with elevated IGF1 and IGFBP5. Multiplex immunofluorescence in primary PCa confirmed increased PD-L1 in patients with high serum IGF-1, supporting its role in immune evasion. Overall, these findings reveal a novel IGF-1-driven immunosuppressive mechanism that may underlie PCa’s resistance to immunotherapy.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Surgical Sciences
Sub department:
Surgical Sciences
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Surgical Sciences
Sub department:
Surgical Sciences
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Surgical Sciences
Sub department:
Surgical Sciences
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Surgical Sciences
Sub department:
Surgical Sciences
Role:
Author


More from this funder
Funder identifier:
https://ror.org/054225q67
More from this funder
Funder identifier:
https://ror.org/04dkv6329
More from this funder
Funder identifier:
https://ror.org/052gg0110


Publisher:
Nature Research
Journal:
Scientific Reports More from this journal
Volume:
15
Issue:
1
Article number:
38422
Publication date:
2025-11-03
Acceptance date:
2025-09-26
DOI:
EISSN:
2045-2322
ISSN:
2045-2322


Language:
English
UUID:
uuid_d2cdaf98-aced-4a71-a013-f5351252a0d8
Source identifiers:
3435348
Deposit date:
2025-11-03
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP